ONCOCYTE CORPORATION

(OCX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

OncoCyte Strikes Deal with Thermo Fisher to Expand Access to Precision Oncology

01/18/2022 | 04:33pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ON SEMICONDUCTOR CORPORATION -2.49% 54.5 Delayed Quote.-19.76%
ONCOCYTE CORPORATION -8.86% 0.9843 Delayed Quote.-54.64%
THERMO FISHER SCIENTIFIC -1.15% 548.82 Delayed Quote.-16.79%
All news about ONCOCYTE CORPORATION
05/24Stephens Downgrades OncoCyte to Equalweight From Overweight, Adjusts Price Target to $1..
MT
05/16Piper Sandler Trims OncoCyte's Price Target to $1.40 From $1.80, Maintains Overweight R..
MT
05/12ONCOCYTE CORP Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/12Needham Adjusts OncoCyte's Price Target to $2.25 From $4 on 'Peer Multiple Compression,..
MT
05/11ONCOCYTE : Q1 Earnings Snapshot
AQ
05/11TRANSCRIPT : OncoCyte Corporation, Q1 2022 Earnings Call, May 11, 2022
CI
05/11ONCOCYTE CORP : Results of Operations and Financial Condition, Change in Directors or Prin..
AQ
05/11OncoCyte Corporation Reports Earnings Results for the First Quarter Ended March 31, 202..
CI
05/11Oncocyte Reports First Quarter 2022 Financial Results
AQ
05/11Earnings Flash (OCX) ONCOCYTE CORPORATION Posts Q1 Revenue $1.4M
MT
More news
Analyst Recommendations on ONCOCYTE CORPORATION
More recommendations
Financials (USD)
Sales 2022 9,30 M - -
Net income 2022 -50,8 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,01x
Yield 2022 -
Capitalization 121 M 121 M -
Capi. / Sales 2022 13,0x
Capi. / Sales 2023 5,79x
Nbr of Employees 113
Free-Float 91,9%
Chart ONCOCYTE CORPORATION
Duration : Period :
OncoCyte Corporation Technical Analysis Chart | OCX | US68235C1071 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 0,98 $
Average target price 3,15 $
Spread / Average Target 220%
EPS Revisions
Managers and Directors
Ronald Asbury Andrews President, Chief Executive Officer & Director
Mitchell Stuart Levine Chief Financial Officer
Andrew Arno Chairman
Douglas T. Ross Chief Science Officer
Ekkehard Schütz Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
ONCOCYTE CORPORATION-54.64%121
GILEAD SCIENCES, INC.-11.38%79 850
REGENERON PHARMACEUTICALS, INC.8.63%73 473
VERTEX PHARMACEUTICALS22.26%68 632
WUXI APPTEC CO., LTD.-22.20%42 378
BIONTECH SE-36.69%39 666